MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Total Assets 2011-2026 | ZOM
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127 M | 207 M | 253 M | 280 M | 280 M | 63 K | 4.18 M | 6.03 M | 5.22 M | 82.1 K | 145 K | 212 K | 97.3 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 280 M | 63 K | 89.5 M |
Quarterly Total Assets Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 131 M | 136 M | 143 M | 207 M | 214 M | 220 M | - | 253 M | 275 M | 275 M | 280 M | 280 M | 282 M | 275 M | 278 M | 280 M | 278 M | 280 M | 280 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 4.18 M | 4.18 M | 4.18 M | 4.18 M | 6.03 M | 6.03 M | 6.03 M | 6.03 M | 5.22 M | 5.22 M | 5.22 M | 5.22 M | 4.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 282 M | 4.18 M | 134 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 4.06 | 4.1 % | $ 57.1 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.68 | 3.08 % | $ 1.37 B |  Canada |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.63 | 1.53 % | $ 2.05 B | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.35 | 0.86 % | $ 309 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.19 | -2.87 % | $ 128 M | Canada |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 24.51 | -3.35 % | $ 1.13 B | USA |
 |
Harrow Health
HROW
|
399 M | $ 39.7 | 2.45 % | $ 1.46 B | USA |
 |
Jupiter Wellness
JUPW
|
41 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 1.14 | -36.67 % | $ 1.41 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.45 | 0.7 % | $ 402 M | Canada |
 |
Tilray
TLRY
|
4.31 B | $ 6.75 | -2.74 % | $ 4.17 B | Canada |
 |
Evolus
EOLS
|
226 M | $ 5.3 | -0.19 % | $ 342 M | USA |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.51 | -1.31 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.03 | -0.74 % | $ 411 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.32 | 0.43 % | $ 313 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
Viatris
VTRS
|
50 B | $ 14.59 | -1.08 % | $ 17.5 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 1.01 | - | $ 4.36 M | USA |
 |
Assertio Holdings
ASRT
|
267 M | $ 18.04 | 0.11 % | $ 116 M | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 7.92 | -3.65 % | $ 693 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 7.21 | -0.55 % | $ 285 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 1.02 | -2.86 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.39 | 3.35 % | $ 86.3 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
57.1 M | $ 0.87 | 1.99 % | $ 31.3 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
31 M | $ 0.61 | 1.65 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
37.7 M | $ 2.19 | 0.46 % | $ 25.3 M | USA |